ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 739.1 | 647.3 | 1221.0 |
| Other income | 77.8 | 58.1 | 66.3 |
| Total income | 816.9 | 705.4 | 1287.3 |
| Profit before exceptional items & tax | 144.1 | 161.1 | 505.9 |
| Profit before tax | 144.1 | 161.1 | 505.9 |
| Net profit | 269.0 | 151.3 | 406.0 |
| Operating margin | 17.6% | 22.8% | 39.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -33.70% |
|---|---|
| Net profit, quarter on quarter | +77.80% |
| Revenue, year on year | -39.50% |
BSE results filing, NSE: NATCOPHARM. Figures extracted from the filing.
Natco Pharma Ltd: key numbers
- Share price
- ₹808.95
- Market cap
- ₹15,869 Cr
- Revenue (annual)
- ₹4,078 Cr
- Net profit (annual)
- ₹1,418 Cr
- P/E (TTM)
- 13.9×Sector 43.8×
- Promoter holding
- 46.22%-3.20% QoQ
- FII holding
- 15.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Natco Pharma Ltd
All →Natco Pharma Share Pledge
Natco Pharma promoter V.C. Nannapaneni pledged 8,50,000 equity shares to Bajaj Financial Securities Limited. The pledge supports the promoter's subscription to the company's Rights Issue.
Natco Pharma Other Announcement
Natco Pharma filed its shareholding pattern with a reporting date of 23 October 2026. Promoter and promoter group hold about 46% of total equity.
Natco Pharma Capital Structure Change
Natco Pharma allotted 5,86,666 equity shares to promoter Venkaiah Chowdary Nannapaneni via its rights issue, valued at ~₹44 Crore. This lifts his stake to 14.60%.
- Value
- ₹44.00 Cr
Natco Pharma Employee Stock Options
Natco Pharma's insiders, including promoters and directors, were allotted equity shares. This allotment increases their total shareholding in the company.
- Value
- ₹144.2 Cr
Natco Pharma Board Meeting Date
Natco Pharma will hold a board meeting on 13 November 2026 to consider unaudited quarterly results and an interim dividend. Trading window closed until 15 November 2026.
Natco Pharma Capital Structure Change
Natco Pharma's ₹1,279.4 Crore rights issue closed on October 22, 2026. Shares were priced at ₹750 each on a ₹2 face value.
- Value
- ₹1,279 Cr